U.S. market Open. Closes in 4 hours 12 minutes

NLTX | Neoleukin Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
RevenueN/A6.00K451.00KN/A25.00MN/AN/AN/AN/AN/AN/A
Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Gross ProfitN/A6.00K451.00KN/A25.00MN/AN/AN/AN/AN/AN/A
Operating Expenses59.10M60.70M41.55M23.24M57.62M51.12M37.65M21.34M22.38MN/AN/A
Selling, General & Admin17.97M21.54M17.21M18.83M15.84M14.85M9.26M5.54M4.30M1.78M1.64M
Research & Development41.13M39.16M24.34M4.42M41.79M36.27M28.38M15.80M18.08M7.54M6.05M
Other Operating Expenses-42.00K6.00K-44.00K-8.00K-445.00KN/AN/AN/AN/AN/AN/A
Operating Income-59.10M-60.70M-33.73M-70.96M-32.62M-51.12M-37.65M-21.34M-22.38M-9.38M-7.68M
Other Expenses / Income1.54M6.00K451.00K1.52M-520.00K936.00K643.00K-520.00K-1.65M641.24K9.11K
Before Tax Income-57.56M-60.69M-33.28M-69.44M-31.59M-50.18M-37.00M-21.86M-24.03M-8.73M-7.67M
Income Tax Expenses-1.54M-2.28M-8.32M-7.00K-1.04MN/AN/AN/A-222.00-5.04K42.29K
Net Income-56.02M-58.41M-24.96M-69.44M-31.59M-50.18M-37.00M-21.86M-24.03M-8.73M-7.71M
Interest Expenses1.58MN/AN/A1.00K4.00K4.00K1.00K99.00K461.59K42.92K9.47K
Basic Shares Outstanding11.04M11.01M10.37M5.41M4.70M23.45M18.89M12.64M8.67M5.85M5.85M
Diluted Shares Outstanding11.04M11.01M10.37M5.41M4.70M23.45M18.89M12.64M8.67M5.85M5.85M
EBITDA-56.48M-60.70M-47.56M-21.37M-31.51M-50.18M-37.07M-21.71M-22.24M-9.68M-7.53M
EBITDA Margin0.00%-1,011,633.33%-10,546.34%0.00%-126.02%0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-55.98M-60.69M-33.28M-69.44M-32.62M-50.18M-37.00M-21.76M-23.57M-8.69M-7.66M
EBIT Margin0.00%-1,011,533.33%-7,378.49%0.00%-130.50%0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙